Dextrose
Dextrose is a form of glucose (sugar) given intravenously to treat low blood sugar (hypoglycemia) and to supply calorie and nutritional support when a patient cannot eat or absorb food normally.
🧬 Where this information comes from Click to expand
The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 45 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →
📖 Dextrose: Patient Information Guide
A plain-language walkthrough of Dextrose — what it treats, how it works, how it’s taken, side effects, warnings and interactions. Tap any section to expand it.
🎯What it's used for▾
Dextrose injection is used across several clinical situations depending on the specific product and concentration:
- Dextrose Monohydrate (50% injection): Treats insulin hypoglycemia (low blood sugar from too much insulin) and, after dilution, supplies carbohydrate calories by IV when a patient cannot eat adequately
- Infant Dextrose (25% injection): Treats acute symptomatic low blood sugar episodes in pediatric patients from birth up to 2 years old
- Dextrose (25% injection): Treats acute low blood sugar in newborns and older infants; also provides a minimal source of calorie support
- Dextrose (70% solution): Used as the caloric component of parenteral (IV) nutrition — especially when the gut cannot be used, protein absorption is impaired, or protein needs are greatly elevated (e.g., extensive burns)
- Dextrose (10% concentrated injection): Mixed with amino acids or diluted with other IV fluids to deliver parenteral nutrition at a final 5% dextrose concentration
- Dextrose injection (standard formulation): Provides water and calories intravenously and serves as a diluent to reconstitute certain drug products packaged in vials
- Parenteral 50% Dextrose injection: Treats insulin hypoglycemia and, after dilution, provides carbohydrate calories for patients with inadequate oral intake
⚙️How it works▾
Dextrose is glucose — the primary fuel your body runs on. When injected directly into the bloodstream, it is immediately available to cells throughout the body. Cells take up the glucose and break it down through a process called oxidation, producing carbon dioxide, water, and — most importantly — energy. In someone experiencing hypoglycemia (low blood sugar), this rapidly restores normal blood glucose and relieves dangerous symptoms. In patients who cannot eat, it delivers essential caloric energy to keep the body functioning.
💊How it's taken▾
Dextrose is given only by intravenous (IV) infusion or injection in a medical setting — never taken by mouth in these forms. The specific concentration, infusion rate, and duration are determined individually by a prescriber based on the patient's age, weight, blood glucose levels, and overall clinical condition.
- Lower concentrations (such as 5%) may be given through a peripheral vein (arm); higher concentrations or high-osmolarity solutions must go through a central vein to protect smaller veins from damage
- Concentrated solutions (such as the 70% formulation) are never given directly — they must first be diluted or mixed with amino acid solutions before infusion
- Infant Dextrose (25%) is given by slow IV injection into a central vein in infants; it must never be injected under the skin or into a muscle
- Always follow your care team's instructions exactly — infusion rate and duration will be adjusted based on ongoing blood glucose and lab monitoring
🤒Side effects — in detail▾
The most common side effects reported with dextrose injection include:
- High blood sugar (hyperglycemia)
- Low sodium in the blood (hyponatremia)
- Vein irritation, redness, pain, or swelling at the infusion site
- Vein clotting (thrombosis or phlebitis)
- Infection at the IV site or throughout the body (sepsis)
- Fluid overload (swelling, congestion, or fluid in the lungs)
- Allergic reactions (rash, itching, swelling, low blood pressure)
More serious reactions — including pulmonary embolism (blood clot in the lungs), severe electrolyte imbalances, hyponatremic encephalopathy (brain swelling from low sodium), and liver disease — have also been reported. Contact your care team immediately if you develop trouble breathing, confusion, seizures, chest pain, or signs of severe allergic reaction.
⚠️Warnings & precautions▾
- High blood sugar (hyperglycemia): Infusing dextrose too fast or at too high a concentration can cause blood sugar to rise dangerously — potentially leading to coma or death. Blood glucose is monitored continuously and insulin may be used to keep levels in a safe range.
- Low sodium (hyponatremia): As glucose is metabolized, fluid can shift and pull sodium levels dangerously low, especially in children, older adults, premenopausal women, and people with brain or kidney conditions. Severe hyponatremia can cause seizures, brain swelling, and death.
- Vein damage and clotting: High-concentration solutions must be given through a central vein. Peripheral vein use with concentrated dextrose can cause thrombophlebitis (painful vein inflammation and clotting).
- Pulmonary embolism: Precipitates (particles) can form in IV lines and cause life-threatening blockages in the lungs. The infusion set should be checked regularly; stop the infusion immediately if breathing problems develop.
- Aluminum toxicity: Dextrose solutions contain trace aluminum. In patients with kidney impairment — especially premature infants — aluminum can build up and damage the nervous system and bones.
- Infection risk: IV catheters and nutrient-rich solutions can support bacterial growth. Signs of infection (fever, chills, redness at the IV site) should be reported promptly.
- Liver disease (PNALD): Long-term parenteral nutrition with dextrose can cause liver damage, particularly in premature infants. Liver function is monitored throughout treatment.
- Refeeding syndrome: Severely malnourished patients restarting nutrition can develop dangerous shifts in potassium, phosphorus, and magnesium. Nutrient intake is increased slowly to prevent this.
🔀What it interacts with▾
Dextrose injection can interact with several types of medications, primarily by affecting blood sugar, sodium levels, and fluid balance:
- Diuretics (water pills): Increase the risk of low sodium (hyponatremia) when combined with dextrose infusion
- SSRIs and SNRIs (certain antidepressants): Associated with low sodium on their own; risk increases when used alongside dextrose
- Antiepileptic (anti-seizure) medications: Certain agents are linked to hyponatremia; use with dextrose requires close sodium monitoring
- Arginine vasopressin analogs and certain psychotropic or cytotoxic drugs: Can cause low sodium (SIADH); avoid concurrent use with dextrose when possible, or monitor sodium very closely
- Insulin: Blood glucose must be monitored carefully; insulin doses may need adjustment during dextrose infusion to prevent hyperglycemia
- Blood products: Never mix or infuse through the same line simultaneously — dextrose can cause red blood cell clumping (pseudoagglutination) or destruction (hemolysis)
This is not a complete list of interactions. Always talk with your doctor or pharmacist before starting, stopping, or changing any medication.
📋Before taking it▾
- Severe dehydration: Hypertonic dextrose solutions are contraindicated — they can worsen the body's hyperosmolar (concentrated fluid) state
- Known allergy to dextrose: Contraindicated; tell your care team about any prior reactions
- Impaired glucose tolerance or diabetes: Dextrose infusion can worsen high blood sugar; close monitoring is required
- Kidney impairment: Increases the risk of aluminum toxicity from prolonged dextrose use; also raises risk of fluid and electrolyte imbalances
- Premature and low-birth-weight infants: At significantly higher risk of blood sugar swings, electrolyte problems, aluminum toxicity, and brain bleeding — require very careful dose selection
- Older adults: More likely to have reduced kidney function and are at higher risk of low sodium and related brain complications; start at lower doses with careful monitoring
- Pregnancy: Dextrose infusion during pregnancy is generally appropriate when nutritionally necessary, but high blood sugar near delivery can cause low blood sugar in the newborn — inform your care team
- Heart or lung disease: High-volume infusion can cause fluid overload and pulmonary edema (fluid in the lungs); requires close monitoring
- Severely malnourished patients: At risk of refeeding syndrome when nutrition is restarted; dextrose is introduced slowly with lab monitoring
🚑If you take too much▾
Receiving dextrose too fast or in too high a concentration can cause severely high blood sugar (hyperglycemia), an overly concentrated blood state (hyperosmolality), and dangerous imbalances in fluids and electrolytes — including severely low sodium — which can be fatal. If this occurs, the infusion is stopped and corrective measures are started, which may include insulin to lower blood sugar. If there is concern about overexposure, the Poison Control Center can be reached at 1-800-222-1222.
📡Pharmacodynamics — effects in the body▾
Dextrose raises blood glucose levels when given intravenously, which is the primary therapeutic effect in patients with hypoglycemia. The precise relationship between the dose given and how quickly or strongly blood glucose responds has not been fully characterized in clinical studies. In patients receiving parenteral nutrition, dextrose provides measurable caloric energy to support the body's metabolic needs.
🔬Pharmacokinetics — how your body processes it▾
Once in the bloodstream, dextrose (glucose) is taken up by cells and broken down — a process called oxidation — into carbon dioxide and water, releasing energy in the process. This is the same pathway the body uses to metabolize glucose from food.
📦How to store it▾
STORE AT: 20° to 25 °C ( 68° to 77° F) ; brief exposure up to 40°C/104°F does not adversely affect the product.
📄 Written from Dextrose’s FDA-approved label information, summarized in plain language with AI, and reviewed by our pharmacy team before publication. Every point is grounded in that labeling — nothing is invented. How we use AI →
🩺 Pharmacist Counseling Corner
Quick, plain-English answers to the questions patients ask most about Dextrose — the kind of thing our pharmacy team would talk through with you at the counter.
What is dextrose actually used for? ▾
Is dextrose safe for my baby or newborn? ▾
What side effects should I watch for during a dextrose infusion? ▾
Can dextrose interact with my other medications? ▾
I'm pregnant — is dextrose safe? ▾
What happens if I get too much dextrose? ▾
Is Dextrose available over the counter? ▾
When was Dextrose first available? ▾
Who makes Dextrose? ▾
💬 Answers drafted from Dextrose’s FDA-approved label information, summarized in plain language with AI, and reviewed by our pharmacy team before publication. Grounded in that labeling — nothing is made up. How we use AI →
🧰 Keep exploring
💊 How Dextrose comes
Dextrose is available in 1 form. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Injection
How this form is used
- Dextrose Monohydrate (50%) is used to treat insulin-induced low blood sugar (hypoglycemia) and, after dilution, to provide carbohydrate calories via IV when oral intake is insufficient
- Infant Dextrose (25%) is indicated for acute symptomatic low blood sugar in pediatric patients from birth up to 2 years of age
- Dextrose (25% injection) treats acute low blood sugar episodes in newborns and older infants and provides a minimal source of calorie support
- Dextrose (70% solution) and the 10% concentrated injection are used as caloric components in parenteral (IV) nutrition regimens, including in patients with severe burns or impaired protein absorption; Dextrose injection is also used as a source of water and calories and as a drug diluent
- Infant Dextrose (25%) must be given by slow intravenous injection into a central vein only — never subcutaneously or intramuscularly; blood glucose should be checked before administration when possible
- Dextrose Monohydrate and Parenteral 50% injections should be infused slowly; rapid infusion of hypertonic solutions can cause high blood sugar
- Do not administer any dextrose injection simultaneously with blood products through the same IV line — red blood cell clumping may occur
- High-concentration or high-osmolarity dextrose solutions (greater than 5% or osmolarity of approximately 900 mOsm/L or more) must be administered through a central vein to avoid vein damage
Show 13 more strengths Show fewer strengths
📊 Dextrose across the U.S. market
How Dextrose appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
Also listed with the FDA, not a patient dose form: Powder (4) — bulk drug substance sold to compounders/manufacturers and multi-item kits. These aren’t counted in the dose-form total above.
Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
📈 How widely Dextrose is used
A general measure of how commonly Dextrose is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.
Think of this as a proxy for how widely Dextrose is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.
How commonly is Dextrose prescribed? Of the 1,596 medications we measure, Dextrose ranks #430 by Medicaid prescriptions — more than 73% of them.
Utilization by Dextrose product
Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.
glucose 700 MG/ML Injectable Solution Most dispensed
Summed across the 4 of 8 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 237656
250 ML glucose 50 MG/ML Injection
Summed across the 8 of 23 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1795610
50 ML glucose 50 MG/ML Injection
Summed across the 10 of 28 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1795616
500 ML glucose 50 MG/ML Injection
Summed across the 7 of 20 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1795607
100 ML glucose 50 MG/ML Injection
Summed across the 10 of 32 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1795609
1000 ML glucose 50 MG/ML Injection
Summed across the 4 of 19 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1795612
25 ML glucose 50 MG/ML Injection
Summed across the 2 of 3 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1795618
50 ML glucose 500 MG/ML Prefilled Syringe
Summed across the 2 of 19 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 727517
1000 ML glucose 100 MG/ML Injection
Summed across the 3 of 7 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1795481
250 ML glucose 100 MG/ML Injection
Summed across the 3 of 8 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1795480
500 ML glucose 100 MG/ML Injection
Summed across the 2 of 9 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1795477
50 ML glucose 500 MG/ML Injection
Summed across the 1 of 5 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1795514
150 ML glucose 50 MG/ML Injection
Summed across the 1 of 4 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1795621
500 ML glucose 500 MG/ML Injection
Summed across the 1 of 2 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1795518
500 ML glucose 200 MG/ML Injection
Summed across the 1 of 1 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 237649
Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.
Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Dextrose, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 59 of 188 listed Dextrose NDCs with Medicaid activity.
🔍 Compare Dextrose products
A representative set of FDA-listed product records for Dextrose — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Injection | ||||
| 25 g/50 mL | Intravenous | A-S Medication Solutions | NDA | Find on DailyMed ↗ |
| 50 mg/mL | Intravenous | B. Braun Medical Inc. × 3 listings | NDA | View NDC → |
| 2.5 g/50 mL | Intravenous | Baxter Healthcare Company × 7 listings | NDA | View NDC → |
| 5 g/100 mL | Intravenous | Baxter Healthcare Company × 9 listings | NDA | View NDC → |
| 2.5 g/50 mL | Intravenous | Baxter Healthcare Corporation × 14 listings | NDA | View NDC → |
| 5 g/100 mL | Intravenous | Baxter Healthcare Corporation × 40 listings | NDA | View NDC → |
| 50 g/1000 mL | Intravenous | Baxter Healthcare Corporation × 4 listings | NDA | View NDC → |
| 70 g/100 mL | Intravenous | Baxter Healthcare Corporation × 3 listings | NDA | View NDC → |
| 100 g/1000 mL | Intravenous | Baxter Healthcare Corporation × 4 listings | NDA | View NDC → |
| 50 mg/mL | Intravenous | Becton Dickinson and Company × 2 listings | ANDA | View NDC → |
| 100 mg/mL | Intravenous | Becton Dickinson and Company × 2 listings | ANDA | View NDC → |
| 2500 mg/50 mL | Intravenous | Becton Dickinson And Company | ANDA | View NDC → |
| 50 mg/mL | Intravenous | Fresenius Kabi Usa, Llc × 8 listings | ANDA | View NDC → |
| 100 mg/mL | Intravenous | Fresenius Kabi USA, LLC × 2 listings | ANDA | View NDC → |
| 2500 mg/50 mL | Intravenous | Fresenius Kabi USA, LLC × 2 listings | ANDA | View NDC → |
| 5000 mg/100 mL | Intravenous | Fresenius Kabi USA, LLC × 2 listings | ANDA | View NDC → |
| 12500 mg/250 mL | Intravenous | Fresenius Kabi USA, LLC × 2 listings | ANDA | View NDC → |
| 25000 mg/500 mL | Intravenous | Fresenius Kabi USA, LLC × 2 listings | ANDA | View NDC → |
| 250 mg/mL | Intravenous | General Injectables & Vaccines, Inc | NDA | View NDC → |
| 25 g/50 mL | Intravenous | General Injectables & Vaccines, Inc × 4 listings | NDA | View NDC → |
| 25 g/50 mL | Intravenous | General Injectables & Vaccines, Inc. | UNAPPROVED DRUG OTHER | View NDC → |
| 250 mg/mL | Intravenous | Henry Schein, Inc. × 4 listings | NDA | View NDC → |
| 25 g/50 mL | Intravenous | Henry Schein, Inc. × 6 listings | NDA | View NDC → |
| 25 g/50 mL | Intravenous | Henry Schein, Inc. × 2 listings | UNAPPROVED DRUG OTHER | View NDC → |
| 100 mg/mL | Intravenous | HF Acquisition Co. LLC. DBA HealthFirst | ANDA | View NDC → |
| 500 mg/mL | Parenteral | HF Acquisition Co LLC, DBA HealthFirst × 2 listings | UNAPPROVED DRUG OTHER | View NDC → |
| 5 g/100 mL | Intravenous | HF Acquisition Co LLC, DBA HealthFirst × 3 listings | NDA | View NDC → |
| 25 g/50 mL | Intravenous | HF Acquisition Co LLC, DBA HealthFirst × 2 listings | UNAPPROVED DRUG OTHER | View NDC → |
| 25 g/50 mL | Intravenous | HF Acquisition Co LLC, DBA HealthFirst × 3 listings | ANDA | View NDC → |
| 25 g/50 mL | Intravenous | HF Acquisition Co LLC, DBA HealthFirst × 3 listings | NDA | View NDC → |
| 50 mg/mL | Intravenous | Hospira, Inc. × 2 listings | NDA | View NDC → |
| 250 mg/mL | Intravenous | Hospira, Inc. × 4 listings | NDA | View NDC → |
| 25 g/50 mL | Intravenous | Hospira, Inc. × 11 listings | NDA | View NDC → |
| 25 g/50 mL | Intravenous | Hospira, Inc. | UNAPPROVED DRUG OTHER | View NDC → |
| 5 g/100 mL | Intravenous | ICU Medical, Inc. × 2 listings | NDA | View NDC → |
| 10 g/100 mL | Intravenous | ICU Medical, Inc. | NDA | View NDC → |
| 5 g/100 mL | Intravenous | ICU Medical Inc. × 6 listings | NDA | View NDC → |
| 10 g/100 mL | Intravenous | ICU Medical Inc. × 2 listings | NDA | View NDC → |
| 20 g/100 mL | Intravenous | ICU Medical Inc. × 3 listings | NDA | View NDC → |
| 30 g/100 mL | Intravenous | ICU Medical Inc. × 3 listings | NDA | View NDC → |
| 40 g/100 mL | Intravenous | ICU Medical Inc. × 3 listings | NDA | View NDC → |
| 50 g/100 mL | Intravenous | ICU Medical Inc. × 3 listings | NDA | View NDC → |
| 70 g/100 mL | Intravenous | ICU Medical Inc. × 6 listings | NDA | View NDC → |
| 500 mg/mL | Parenteral | International Medication Systems, Limited | UNAPPROVED DRUG OTHER | View NDC → |
| 25 g/50 mL | Intravenous | International Medication Systems, Limited × 2 listings | ANDA | View NDC → |
| 250 mg/mL | Intravenous | Medical Purchasing Solutions, LLC × 2 listings | NDA | View NDC → |
| 500 mg/mL | Parenteral | Medical Purchasing Solutions, LLC × 2 listings | UNAPPROVED DRUG OTHER | View NDC → |
| 25 g/50 mL | Intravenous | Medical Purchasing Solutions, LLC × 3 listings | NDA | View NDC → |
| 25 g/50 mL | Intravenous | Medical Purchasing Solutions, LLC | UNAPPROVED DRUG OTHER | View NDC → |
| 25 g/50 mL | Intravenous | Medical Purchasing Solutions, LLC | ANDA | View NDC → |
| 50 mg/mL | Intravenous | ProPharma Distribution | ANDA | View NDC → |
Showing 200 of 217 products — FDA National Drug Code Directory. See every product, package size and price: browse all 217 Dextrose NDCs →
📈 What people report — real-world data (FDA FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Dextrose — a signal of what to watch for, not proof the drug caused it.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Dextrose in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
🏛️ The road to your pharmacy
How Dextrose went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Source: Drugs@FDA.
🚨 Recall history
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
Source: openFDA drug enforcement (recall) reports.
RxNorm Concept Web — From Ingredient to Every Form and Strength
This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.
RxCUI 4850 7 dose forms · 43 strengths
-
Dose form (SCDF) Chewable Tablet RxCUI 372326No current FDA listingClinical drug / strength (SCD) 1000 MGRxCUI 8914513750 MGRxCUI 25313684000 MGRxCUI 3105195000 MGRxCUI 31052015000 MGRxCUI 2473284 -
Dose form (SCDF) Injectable Solution RxCUI 376937In current FDA listingsClinical drug / strength (SCD) Shortage Import Unapproved glucose 500 MG/MLRxCUI 2698763Shortage Import Unapproved glucose 700 MG/MLRxCUI 269876450 MG/MLRxCUI 309778150 MG/MLRxCUI 107097250 MG/MLRxCUI 260258500 MG/MLRxCUI 237653600 MG/MLRxCUI 237654700 MG/MLRxCUI 237656 -
Dose form (SCDF) Injection RxCUI 1794567In current FDA listingsClinical drug / strength (SCD) 25 ML glucose 50 MG/MLRxCUI 179561850 ML glucose 50 MG/MLRxCUI 179561650 ML glucose 500 MG/MLRxCUI 1795514100 ML glucose 100 MG/MLRxCUI 2262603100 ML glucose 50 MG/MLRxCUI 1795609100 ML glucose 500 MG/MLRxCUI 1996082150 ML glucose 50 MG/MLRxCUI 1795621250 ML glucose 100 MG/MLRxCUI 1795480250 ML glucose 50 MG/MLRxCUI 1795610500 ML glucose 100 MG/MLRxCUI 1795477500 ML glucose 200 MG/MLRxCUI 237649500 ML glucose 300 MG/MLRxCUI 242694500 ML glucose 400 MG/MLRxCUI 237650500 ML glucose 50 MG/MLRxCUI 1795607500 ML glucose 500 MG/MLRxCUI 17955181000 ML glucose 100 MG/MLRxCUI 17954811000 ML glucose 50 MG/MLRxCUI 17956121000 ML glucose 500 MG/MLRxCUI 1795519 -
Dose form (SCDF) Oral Gel RxCUI 377980No current FDA listingClinical drug / strength (SCD) 0.4 MG/MGRxCUI 1986830.417 MG/MGRxCUI 3097740.45 MG/MGRxCUI 16084770.774 MG/MGRxCUI 1598320 -
Dose form (SCDF) Oral Solution RxCUI 239166No current FDA listingClinical drug / strength (SCD) 50 MG/MLRxCUI 200141100 MG/MLRxCUI 200140166.7 MG/MLRxCUI 1052683254 MG/MLRxCUI 849418500 MG/MLRxCUI 95267 -
Dose form (SCDF) Powder for Oral Solution RxCUI 2474503No current FDA listingClinical drug / strength (SCD) 15000 MGRxCUI 2474504 -
Dose form (SCDF) Prefilled Syringe RxCUI 727516No current FDA listingClinical drug / strength (SCD) 10 ML glucose 250 MG/MLRxCUI 72751850 ML glucose 500 MG/MLRxCUI 727517
Look up RxCUI 4850 in the RxCUI Atlas →
RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
📦 Supply & shortage status
Whether Dextrose is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
🏷️ Sold under these brand names
🏭 Manufacturers & labelers
RxNorm drug class
Dextrose belongs to the Other irrigating solutions class.
Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.
🔬 Where this comes from
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How we combine label and product data
HelloPharmacist combines public FDA and NLM records; we don’t author the underlying clinical facts. We identified 45 FDA-filed SPL label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. The representative label is the starting point for the displayed reference monograph; the 12 largest stored in-scope SPL records, which may include that representative, are compared section by section, and the longest available version of each section is retained. Forms, routes, brands, labelers, product-listed strengths, and product-record counts are aggregated separately from ingredient-matched FDA NDC Directory records; package records listed above are associated with the linked SPL; and the normalized concept hierarchy comes from NLM RxNorm.
For canonical ingredient pages, bounded product-attributed indication and administration excerpts may be added to the AI evidence, and the generator is instructed to preserve available product, brand, route, and form qualifiers instead of treating one label as universal. Where a section is identified as AI-written, its plain-language text is generated from bounded label evidence. New draft drug pages remain in the admin review queue before first publication. ICU Medical Inc. is the representative DailyMed label linked for verification and dates; it is not the sole source used for the page.
This is general education, not medical advice — always consult your doctor or pharmacist about your medications and any medical condition. For the exact wording of the linked representative label, view that label on DailyMed; some displayed composite sections may come from other in-scope SPL labels. Learn how we use AI and our data sources & update cadence.